With the EMA’S draft guidance issued just a year ago, it’s crucial to explore how pharma and biotech are navigating its implications and translating it into successful, scalable solutions that are accelerating drugs through regulatory approval.

While Avidity is gaining breakthrough designation for its oligo conjugate, significant challenges persist across the industry.

The Oligonucleotide Analytical Development & CMC will unite 80+ industry experts from analytical development, analytical chemistry, CMC, drug product development, process development, and quality control.

Benefit from case studies, presentations, and deep dive discussions from Sarepta, Ionis, Biogen, Novo Nordisk, GSK, Wave Life Science, and more. Gain insight into their strategy to accelerate analytical development of oligos and innovate scale-up manufacturing processes, all whilst meeting regulatory expectations.

See the event details here.